ArticleResearch and reports in urology2026
The Added Value of Systematic Biopsy in Biopsy-Naïve Patients Undergoing Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Prostate Biopsy.
Article in Research and reports in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The added value of systematic biopsy (SBx) for detection of clinically significant prostate cancer (csPCa) in biopsy-naïve patients undergoing MRI-targeted biopsy (TBx) has been reported. However, the added value of SBx for ISUP upgrading and csPCa localization has not been fully investigated. In this study, we evaluated the added value of SBx in biopsy-naïve patients undergoing MRI-transrectal ultrasound fusion biopsy. Patients and Methods: We retrospectively evaluated 220 consecutive biopsy-naïve men with a prebiopsy positive MRI (PIRADS ≥3) and prostate-specific antigen ≤20 ng/mL who underwent MRI-transrectal ultrasound fusion biopsy and systematic 16-core biopsy. Only TBx data for the index lesion (IL) were used when multiple lesions were present on prebiopsy MRI. The csPCa detection rate (International Society of Urological Pathology grade group [ISUP GG] ≥2) was compared between TBx, SBx, and TBx + SBx. The frequency of potentially missed csPCa by TBx alone was determined. GG discrepancies and csPCa localization were compared between TBx and SBx. Results: The overall csPCa detection rate (TBx + SBx) was 54.5% (120/220). The csPCa detection rate was higher for TBx (50.9%, 112/220) than for SBx (45%, 99/220). TBx alone missed csPCa in 8 patients (6.6%, 8/120). SBx led to GG upgrading in 25 (23.5%) of 106 patients who were positive on both TBx and SBx. Of 110 patients with the IL in the peripheral zone (PZ), 76 (69.0%) were diagnosed with csPCa on TBx and 51 (46.3%) had concomitant csPCa in the transition zone (TZ) on SBx. Of 110 patients with the IL in TZ, 36 (32.7%) were diagnosed with csPCa on TBx and 16 (14.5%) had concomitant csPCa in PZ on SBx. Conclusion: SBx had the added value for the detection of csPCa, GG upgrading, and csPCa localization in biopsy-naïve patients undergoing MRI-transrectal ultrasound fusion biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.